ArticleEJHaem2026
Clinical Profile and Chemotherapy Outcomes of Adult Lymphoma Patients at Jimma University Medical Center: A 2-Year Retrospective Study.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphoma, including Hodgkin (HL) and non-Hodgkin (NHL) subtypes, is a leading non-infectious cause of morbidity and mortality in Ethiopia. Diagnosis relies on histopathology with immunohistochemistry or flow cytometry; staging and prognosis use laboratory tests and imaging. Treatment selection depends on subtype, stage, and resources. This study evaluated clinical features and chemotherapy outcomes among adult lymphoma patients at Jimma University Specialized Hospital Oncology Unit. Method: An institution-based retrospective review of patients treated from April 2022 to March 2024 was performed. Data were abstracted from September to November 2024 using a structured questionnaire capturing socio-demographics, clinical and histopathological findings, treatment regimens, and outcomes. Descriptive statistics summarized frequencies and proportions; results are presented in tables and graphs. Result: Among 197 patients, 85% had NHL and 15% HL. NHL predominated in older adults (43.7% aged 46-60); HL clustered in younger patients (66.7% aged 15-30). Male predominance was observed in both subtypes. High-grade histology occurred in 62.9% of NHL; mixed cellularity was the commonest HL subtype (36.7%). Most presented at Stage 2 (37.6%) or Stage 3 (36.5%); head and neck nodal disease (30.1%) and extranodal involvement (45.2%), mainly spleen, were frequent. Lymphadenopathy (47.8%) and B symptoms (42.0%) were common; hypertension was the leading comorbidity (56.6%). Elevated LDH was frequent in both groups (∼90%). All HL patients received ABVD; 83.8% of NHL patients received CHOP, and 94.4% completed six cycles. Complete remission rates were 60% for HL and 49.7% for NHL; 11.7% required second-line therapy. Conclusion: NHL predominates in older adults while HL affects younger patients. Late intermediate-stage presentation, high comorbidity burden, and limited access to targeted agents likely contributed to lower remission in NHL, highlighting the need for earlier diagnosis, risk stratification, and resource-appropriate treatment optimization. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.